Biogen Idec, Inc. (Massachusetts) Release: TYSABRI® (natalizumab) Data at ECTRIMS Reaffirm Positive Effects of Treatment for People With Relapsing Forms of MS

WESTON, Mass. & DUBLIN--(BUSINESS WIRE)--Today, Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that results from 11 company-sponsored TYSABRI presentations, including 10 posters and one platform, will be available for viewing at the 28TH Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10 – 13. Key data highlights from ECTRIMS include: Long-term safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the TYSABRI Observational Program (TOP) – Poster 519.